Corona Virus Disease 2019 (COVID-19) Clinical Trial
Official title:
Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach
| Verified date | December 2020 |
| Source | University of Lahore |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose
| Status | Completed |
| Enrollment | 200 |
| Est. completion date | December 10, 2020 |
| Est. primary completion date | December 10, 2020 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy Exclusion Criteria: Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent |
| Country | Name | City | State |
|---|---|---|---|
| Pakistan | The University of Lahore | Lahore | Punjab |
| Lead Sponsor | Collaborator |
|---|---|
| University of Lahore |
Pakistan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen | 7 days | ||
| Secondary | Hospital stay | 15 days | ||
| Secondary | Oxygen demand | 7-15 days | ||
| Secondary | Viral load | by RT-PCR | 7-15 days |